Trials / Completed
CompletedNCT01520103
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- AIO-Studien-gGmbH · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorebine, Everolimus | Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress |
| DRUG | Vinorelbine | Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2016-10-31
- Completion
- 2016-10-31
- First posted
- 2012-01-27
- Last updated
- 2017-08-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01520103. Inclusion in this directory is not an endorsement.